Ovarian stimulation methods at a single-assisted reproductive technology institution: a retrospective study of successful outcomes

Author:

Horibe Y.1ORCID,Nakabayashi A.1,Murata S.1,Hashimoto T.1,Tabata T.1

Affiliation:

1. Tokyo Women's Medical University

Abstract

Aim: to examine an efficacy of various stimulation methods in a group of successful pregnancies.Materials and Methods. In a single center retrospective study 47 pregnancy cases were examined after performing embryo transfers at our institution from the years 2017 to 2021. Patients were divided into four groups: i) clomiphene hyperstimulation (CH), ii) stimulation with gonadotropin-releasing hormone (GnRH) agonist, iii) with GnRH antagonist, and iv) progestin-primed ovarian stimulation (PPOS). Age, anti-Mullerian hormone, presence of chronic disease, number of in-vitro fertilizations prior to conception, dosage of follicle stimulating hormone (FSH), presence of premature luteinizing hormone surge, number of egg retrievals, fertilization rate, and live birth rate were assessed.Results. The number of pregnancies obtained by CH, agonist, antagonist, and PPOS methods comprised 25, 12, 2, and 8 cases, respectively. No significant difference in parameters between CH group and non-CH groups, excepting FSH was observed. The FSH was used in CH group and non-CH group at dose of 1108 ± 468 IU and 1756 ± 394 IU, respectively (p < 0.0001).Conclusion. CH is not commonly used due to potential luteal phase defects, but it is thought to be cost-effective, requiring lower FSH doses, requiring no ovulation suppression antagonists, and exerting no effect on frozen embryos or fetuses. Hence, CH could be a suitable protocol for egg retrieval in Japan.

Publisher

IRBIS

Subject

Obstetrics and Gynecology,Embryology,Reproductive Medicine

Reference18 articles.

1. Ishihara O., Jwa S.C., Kuwahara A. et al. Assisted reproductive technology in Japan: a summary report for 2017 by the Ethics Committee of the Japan Society of Obstetrics and Gynecology. Reprod Med Biol. 2019;19(1):3–12. https://doi.org/10.1002/rmb2.12307.

2. Pierce N., Mocanu E. Female age and assisted reproductive technology. Glob Reprod Health. 2018;3(2):e9. https://doi.org/10.1097/GRH.0000000000000009.

3. Newman J.E., Paul R.C., Chambers G.M. Assisted reproductive technology in Australia and New Zealand 2018. Sydney: National Perinatal Epidemiology and Statistics Unit, the University of New South Wales, 2020. 93 p. Available at: https://npesu.unsw.edu.au/sites/default/files/npesu/surveillances/Assisted%20Reproductive%20Technology%20in%20Australia%20and%20New%20Zealand%202018_0.pdf. [Accessed: 25.02.2023].

4. Kushnir V.A., Barad D.H., Albertini D.F. et al. Systematic review of worldwide trends in assisted reproductive technology 2004-2013. Reprod Biol Endocrinol. 2017;15(1):6. https://doi.org/10.1186/s12958-016-0225-2.

5. 2020 Survey and Research Project for the Promotion of Support for Children and Child Rearing: Survey and Research on the Actual Condition of Infertility Treatment. Japanese Ministry of Health Labour and Welfare report, 2020. Available at: https://www.mhlw.go.jp/content/000766912.pdf. [Accessed: 25.02.2023].

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3